Key facts
- This page summarizes Mark J. Rosenblum's Form 4 filing for Salarius Pharmaceuticals, Inc. (SLRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 Nov 2025, 16:42.
Mark J. Rosenblum - 20 Nov 2025 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)
- Reporting relationship
- Exec VP Finance, CFO
- Issuer ticker
- SLRX
- Reported as of
- 20 Nov 2025
- Net transaction value
- +$16,000
- SEC form
- 4
- Accepted by SEC
- 20 Nov 2025, 16:42:09 UTC
- Prior SEC filing
- 22 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark J. Rosenblum
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mark J. Rosenblum filed Form 4 for Salarius Pharmaceuticals, Inc. (SLRX) on 20 Nov 2025.
Change
- Previous filing in this sequence was filed on 22 Feb 2024.
- Current net transaction value: +$16,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001329154
Primary reporting owner
Rosenblum Mark J
- Relationship
- Exec VP Finance, CFO
- Address
- C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOMBE BLVD., SUITE X, HOUSTON
- Signature
- /s/ Mark J. Rosenblum
- Signature date
- 20 Nov 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SLRX
transaction
Common Stock
Purchase
- Transaction value
- $16,000
- Shares
- +20,000
- Change %
- +11299%
- Price
- $0.8000
- Shares after
- 20,177
- Date
- 20 Nov 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares beneficially owned following the transaction is adjusted to reflect the reverse stock splits effective on June 16, 2024 and August 17, 2025.
Footnote F2
Includes 20 shares of unvested restricted stock granted on January 3, 2023.